First in class! Nanjing Leads Biolabs Lbl-015 approved by FDA!

Feb 9, 2021

On February 9, 2021, Nanjing Leads Biolabs Biotech Co., Ltd. (hereinafter referred to as LBL) announced that the world's first PD-1/TGF beta RII. dual-function fusion protein LBL-015 injection freeze-drying preparation has been approved by the U.S. Food and Drug Administration (FDA) for clinical trials. It is independently developed by the company. 

Dr Kang Xiaoqiang, CEO and Chairman of Leads Biolabs, said that Nanjing Leads Biolabs is a science-driven and innovative companies with independent research and development. We are based in Nanjing, facing the world. LBL-015 is our third product which was approved by  FDA for clinical trials. The design of LBL-015 has a solid scientific foundation, and numerous studies have shown that TGF beta trap fixation on the surface of T cells is the most effective way to remove TGF beta inhibition of T cells. I am very grateful to the efficient and pragmatic team of Leads Biolabs. I believe that our persistent efforts will certainly benefit patients with cancer diseases.

About Leads Biolabs

Nanjing Leads Biolabs, Inc. (LBL), is a privately owned biotechnology company with clinical phase pharma. It was found by well-experienced antibody drug experts team in Nanjing who has studied in US. Since 2014, the company has been developing antibody drugs with independent intellectual property rights for the treatment of tumors and other major diseases, focusing on unmet medical needs, especially the problems and challenges faced by oncology immunotherapy. The company has more than 10 new tumor immunotherapy antibody projects composed of a rich research and development pipeline on the technology platform of single-target antibody and dual-specific antibody new drug research and development. It will continue to expand innovation to provide patients with safe, effective, accessible and affordable new drugs to meet the unmet medical needs.